Exchange: NASDAQ·Updated 07:32 PM EDT

ARGX News

News
all
press releases
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
More News
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
Zacks
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 10.42% on an annualized basis producing an average annual return of 22.71%. Currently, argenx has a market capitalization of $58.39 billion.read more...
Benzinga
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX) argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)PR NewswireNEW YORK, Oct. 8, 2026ARGX share price fell sharply after a futility finding resulted...
PR Newswire
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Stocktwits
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Zacks
Why Is ARGX Stock Plunging Today?
Argenx said it would discontinue its Phase 3 Unity study of Efgartigimod SC in adults with moderate-to-severe Sjögren’s disease, an autoimmune condition.
Stocktwits
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
Zacks
BMY or ARGX: Which Is the Better Value Stock Right Now?
BMY vs. ARGX: Which Stock Is the Better Value Option?
Zacks
BMY vs. ARGX: Which Stock Is the Better Value Option?
BMY vs. ARGX: Which Stock Is the Better Value Option?
Zacks

Advertisement|Remove ads.